eMed Valuation, Funding & Investors

eMed is valued at $2B as of March 2026.

See full eMed profile

Last eMed valuation

$2B

Series A · Mar 2026

Last eMed funding round

$200M

Series A · Mar 2026

Cumulative funding eMed raised

$200M

across 1 funding round

Key investors in eMed

  • Aon
  • Joe Lonsdale
  • Antonio Gracias
  • Tom Brady
  • Ara Cohen
  • Jeff Aronin

eMed Overview

About eMed

eMed is a New York-based telehealth provider offering on-demand clinical trials and chronic care management programs for GLP-1 medications targeting obesity and type 2 diabetes. The platform connects patients with board-certified clinicians via app-based consultations and at-home biometric kits shipped nationwide. eMed partners with Novo Nordisk for Wegovy distribution and ensures 95 percent adherence through remote monitoring.


Founded

2020

HQ

United StatesMiami, FL

Website

emed.com

Status

Privately held

Customer focus

B2C

Revenue model

Services, Subscription

Valuation

$2B (Mar 2026)

eMed Valuation

eMed is currently valued at $2B, based on its Series A in March 2026.

The $200M round was led by Aon, with participation from R.J. Melman, Joe Lonsdale, Tom Brady, Antonio Gracias, Tom Ricketts and 3 other investors.

eMed valuation by funding round

eMed valuation by funding round
DateStageValuation
Mar 2026Series A$2B

eMed Funding History

eMed has raised a total of $200M across 1 funding round.

eMed funding rounds

eMed funding rounds
DateStageInvestorsRaisedValuation
Mar 2026Series AAon (lead); R.J. Melman; Joe Lonsdale; Tom Brady; Antonio Gracias; Tom Ricketts; Ara Cohen; Jeff Aronin; Linda Yaccarino$200M$2B

Who has invested in eMed?

9 investors have backed eMed across its funding rounds, including Aon, Joe Lonsdale, Antonio Gracias, Tom Brady, Ara Cohen and Jeff Aronin.

Lead investors include Aon.


eMed Investors

Investors in eMed by funding rounds participated
InvestorHQRoundsRoleFirst check
R.J. MelmanUnited StatesUnited States1ParticipantMar 2026
AonUnited StatesLondon1LeadMar 2026
Joe LonsdaleUnited StatesSan Francisco, CA1ParticipantMar 2026
Tom BradyUnited StatesTampa, FL1ParticipantMar 2026
Antonio GraciasUnited StatesChicago, IL1ParticipantMar 2026
Tom RickettsUnited StatesChicago, IL1ParticipantMar 2026
Ara Cohen--1ParticipantMar 2026

This data is available for Pro users. Sign up to see all 9 eMed investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by eMed

eMed has acquired 1 company to date.

Last acquisition by eMed was on January 29th 2024. eMed acquired Science 37 for $38M.


Latest Acquisitions by eMed

Science 37
Description
Science 37 is a Los Angeles-headquartered clinical research organization pioneering decentralized and virtual trials. The company operates an integrated platform with telemedicine investigators and home-health nurses, conducting more interventional virtual trials than competitors. Its model accelerates patient enrollment, improves retention rates, and accesses diverse populations unavailable to traditional site-based studies.
HQ CountryUnited States
HQ City
Los Angeles, CA
Deal Date29 Jan 2024
Valuation$38M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all eMed acquisitions and their M&A valuation multiples.

Start Free Trial

eMed Competitors

eMed competitors include listed companies like Guiyang Longmaster and Medley Inc., and private ones like Clarify Health Solutions, Grow Therapy, Cadence Solutions and Assort Health.

Public and private companies comparable to eMed
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Clarify Health SolutionsUnited StatesSan Francisco, CAPrivate--$1.4B-
Grow TherapyUnited StatesNew York City, NYPrivate$1B-$3B-
Cadence SolutionsUnited StatesNew York City, NYPrivate$35M-$1.2B-
Assort HealthUnited StatesSan Francisco, CAPrivate$3M-$1.2B-
Guiyang LongmasterChinaChinaPublicly listed$44M$5M$482M-
Medley Inc.JapanJapanPublicly listed$236M$32M$459M1.8x

eMed Public Comps

eMed is still privately-owned, but its public comps include Qingdao Baheal Medical, Schrödinger, Ping An Healthcare, Tieto, JMDC, Omnicell, Indegene, Privia Health, EverCommerce and U.S. Physical Therapy.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Qingdao Baheal Medical$1.1B$139M1.9x1.9x15.1x16.8x
Schrödinger$256M($96M)7.6x7.9x(20.3x)(14.0x)
Ping An Healthcare$815M$52M0.9x0.9x13.4x16.9x
Tieto$2.1B$186M1.3x1.4x15.2x7.9x
JMDC$324M$88M5.0x4.6x18.4x17.9x
Omnicell$1.2B$92M1.2x1.1x15.0x8.1x
Indegene$366M$68M3.7x3.3x19.9x18.2x
Privia Health$2.1B$44M1.0x0.9x50.2x15.3x

This data is available for Pro users. Sign up to see all eMed competitors and their valuation data.

Start Free Trial

Common questions about eMed

When was eMed founded?eMed was founded in 2020.
Where is eMed headquartered?eMed is headquartered in Miami, FL, United States.
Is eMed publicly listed?No, eMed is a private, VC-backed company.
What is eMed's valuation?eMed was last valued at $2B in its Series A in March 2026.
How much funding has eMed raised?eMed has raised $200M across 1 funding round.
What was eMed's last funding round?eMed's last funding round was a $200M Series A in March 2026, led by Aon.
Who are eMed's investors?eMed's investors include R.J. Melman, Aon, Joe Lonsdale, Tom Brady, Antonio Gracias, Tom Ricketts, Ara Cohen, Jeff Aronin and Linda Yaccarino.
Which companies are comparable to eMed?Companies comparable to eMed include Clarify Health Solutions, Grow Therapy, Cadence Solutions, Assort Health, Guiyang Longmaster and Medley Inc..
How many companies has eMed acquired?eMed has acquired 1 company, including Science 37.
What was the largest acquisition by eMed?The $38M acquisition of Science 37 in January 2024 is the largest acquisition eMed has made to date.

See companies similar to eMed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial